MECHELEN, BELGIUM -- (MARKET WIRE) -- March 30, 2007 -- Mechelen, Belgium - Galapagos NV (Euronext & LSE: GLPG), an integrated drug discovery company, announces today that it has reached two significant milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering payments of EUR 3.2 million from GSK.
